Literature DB >> 35178177

Increased Molecular Flexibility Widens the Gap between K i and K d values in Screening for Retinoid X Receptor Modulators.

Masaki Watanabe1, Mariko Nakamura-Nakayama1, Michiko Fujihara1,2, Mayu Kawasaki3, Shogo Nakano3, Hiroki Kakuta1.   

Abstract

Screening for small-molecule modulators targeting a particular receptor is frequently based on measurement of K d, i.e., the binding constant between the receptor and the compound of interest. However, K d values also reflect binding at receptor protein sites other than the modulatory site. We designed derivatives of retinoid X receptor (RXR) antagonist CBTF-EE (1) with modifications that altered their conformational flexibility. Compounds 6a,b and 7a,b showed quite similar K d values, but 7a,b exhibited 10-fold higher K i values than those of 6a,b. Further, 6a,b showed potent RXR-antagonistic activity, while 7a,b were inactive. These results suggest that increased conformational flexibility promotes binding at nontarget receptor sites. In this situation, conventional determination of K d is less effective for screening purposes than the determination of K i using a ligand that binds specifically to the site regulating transcriptional activity. Thus, the use of K i values for orthosteric ligands may increase the hit rate in screening active regulatory molecules.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35178177      PMCID: PMC8842113          DOI: 10.1021/acsmedchemlett.1c00575

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  42 in total

1.  Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343.

Authors:  Kayo Yukawa-Takamatsu; Yifei Wang; Masaki Watanabe; Yuta Takamura; Michiko Fujihara; Mariko Nakamura-Nakayama; Shoya Yamada; Shota Kikuzawa; Makoto Makishima; Mayu Kawasaki; Sohei Ito; Shogo Nakano; Hiroki Kakuta
Journal:  J Med Chem       Date:  2020-12-30       Impact factor: 7.446

Review 2.  Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor.

Authors:  Sergio C Chai; Wenwei Lin; Yongtao Li; Taosheng Chen
Journal:  Drug Discov Today       Date:  2019-02-04       Impact factor: 7.851

3.  Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Authors:  Anil Desphande; Gang Xia; LeeAnn J Boerma; Kimberly K Vines; Venkatram R Atigadda; Susan Lobo-Ruppert; Clinton J Grubbs; Fariba L Moeinpour; Craig D Smith; Konstantin Christov; Wayne J Brouillette; Donald D Muccio
Journal:  Bioorg Med Chem       Date:  2013-12-01       Impact factor: 3.641

4.  Unique response pathways are established by allosteric interactions among nuclear hormone receptors.

Authors:  B M Forman; K Umesono; J Chen; R M Evans
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

Review 5.  The RXR heterodimers and orphan receptors.

Authors:  D J Mangelsdorf; R M Evans
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

6.  Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.

Authors:  Shuji Fujii; Fuminori Ohsawa; Shoya Yamada; Ryosuke Shinozaki; Ryosuke Fukai; Makoto Makishima; Shuichi Enomoto; Akihiro Tai; Hiroki Kakuta
Journal:  Bioorg Med Chem Lett       Date:  2010-07-08       Impact factor: 2.823

7.  RXR agonist modulates TR: corepressor dissociation upon 9-cis retinoic acid treatment.

Authors:  Juliana Fattori; Jéssica L O Campos; Tábata R Doratioto; Lucas M Assis; Mariela T Vitorino; Igor Polikarpov; José Xavier-Neto; Ana Carolina M Figueira
Journal:  Mol Endocrinol       Date:  2014-12-26

8.  Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions.

Authors:  Bitoku Takahashi; Kiminori Ohta; Emiko Kawachi; Hiroshi Fukasawa; Yuichi Hashimoto; Hiroyuki Kagechika
Journal:  J Med Chem       Date:  2002-08-01       Impact factor: 7.446

9.  Screening for PPAR Non-Agonist Ligands Followed by Characterization of a Hit, AM-879, with Additional No-Adipogenic and cdk5-Mediated Phosphorylation Inhibition Properties.

Authors:  Helder Veras Ribeiro Filho; Natália Bernardi Videira; Aline Villanova Bridi; Thais Helena Tittanegro; Fernanda Aparecida Helena Batista; José Geraldo de Carvalho Pereira; Paulo Sérgio Lopes de Oliveira; Marcio Chaim Bajgelman; Albane Le Maire; Ana Carolina Migliorini Figueira
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-01       Impact factor: 5.555

Review 10.  Beyond obesity and lifestyle: a review of 21st century chronic disease determinants.

Authors:  Garry Egger; John Dixon
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.